Abstract
Immunomodulatory agents are often combined in organ transplantation to minimize toxicity and to enhance therapeutic effect. Costimulatory blockade of T-cell activation with anti-CD40 ligand monoclonal antibody (anti-CD40L mAb) induces immune unresponsiveness and supports regeneration across nerve allografts. It would be desirable to combine anti-CD40L mAb therapy with the neuroregenerative agent FK506. However, the combination of antibody-based therapies with calcineurin inhibitors has the potential to abrogate immune unresponsiveness. It was hypothesized that nerve regeneration could be enhanced without disrupting anti-CD40L mAb-induced immune unresponsiveness through administration of sub-immunosuppressive doses of FK506.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
